Blood pressure control and cardiovascular risk reduction

Hippokratia

Volumn 11, Issue 3, 2007, Pages 114-119

  Antonakoudis, G ^a   Poulimenos, L ^a   Kifnidis, K ^a   Zouras, C ^a   Antonakoudis, H ^a,b  

^a Asclepeion Hospital   (Greece)

^b EHS   (Greece)

Author keywords

Blood pressure; Cardiovascular risk; Statin

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PLACEBO; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG CHOICE; DRUG INDICATION; DRUG USE; HEALTH PROMOTION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; PATIENT COMPLIANCE; PROTECTION; REVIEW; RISK FACTOR; RISK REDUCTION; STANDARD;

EID: 34547144278     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 2005; 46: 280-286
2. Staessen JA, Li Y, Thijs L, Wang J-G. Blood pressure reduction and cardiovascular prevention; an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28:385-407
3. Stergiou GS Thomopoulou GC, Skeva II, Mountokalakis TD. Prevalence, Awareness, Treatment and Control of Hypertension in Greece-The Didima Study. AJH 1999;12:959-965
4. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on Blood Pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med, 2001; 344:3-10
5. Appel LJ, Moore TJ, Obarzanek E, et al. - For the DASH Collaborative Research Group. N Engl J Med 1997;336:1117-1124
6. AHA Scientific Statement - AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Circulation 2002;106:338-391
7. Allison TG, Cordeiro RS, Miller TD. Prognostic Significance of Exercise-Induced Systemic Hypertension in Healthy Subjects. Am J Cardiol 1999;83:371-375
8. Myers J, Prakash M, Froelicher D, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793-801
9. Singh JP, Larson MG, Manolio TA, et al. Blood Pressure Response During Treadmill Testing as a Risk Factor for New - Onset Hypertension: The Framingham Heart Study. Circulation 1999;99:1831-1836
10. Chapman RH, Benner JS, PEtrill AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165: 1147-1152
11. Julius St, Kjeldsen SE, Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated regimen based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363:2022-2031
12. Vassan RS. Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease. N Engl J Med 2001; 345: 1291-1297
13. Julius S, Nasbitt S, Egen B, et al, for the TROPHY study. Feasibility of Treating Prehypertension with Angiotensin-Receptor Blocker. N Engl J of Med 2006; 354-367
14. WHO. The World Health Report 2003.Available at: http://who.int/whr/2003/ en/index.html
15. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003; 326:1419-1424
16. Hansson L, Zachetti A, Carruthers SG, et al, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351(9118):1755-1762
17. European Society of Hypertension - European Society of Cardiology Guideline Committee. 2003 European Society of Hypertension -European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053
18. Staessen JA, Wang JG, Thijis L. Cardiovascular protection and blood pressure reduction: a metanalysis. Lancet 2001; 358:1305-1315
19. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S; HOPE/HOPE-TOO Study Investigators. Long - term effects of ramipril on cardiovascular events and on diabetes; results of the HOPE Study Extension. Circulation 2005; 112:1339;1346
20. Furberg CD, Wright JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288; 2981-97
21. Dahlof B, Dereveux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003
22. Wier MR. RAAS versus non RAAS Regimens on Cardiovascular Endpoints. J Clin Hypertens 2006; 8 : 99-105
23. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the rennin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta - analysis. Lancet. 2005; 366:2026-2033
24. Giles TD, Berk BC, Black HR, et al, on behalf of the Hypertension Writing Group. Expanding the definition and classification of hypertension. J Clin Hypertens 2005;7:505-512
25. Lloyd-Jones DM, Leip EP, Larson MG. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circualtion 2006; 113:791-798
26. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113:791-798
27. Estimating Coronary Heart Disease (CHD) Risk Using Framingham Heart Study Prediction Score Sheets. Available at http://www.nhibi.nih.gov/about/ framingham/riskabs.htm.Accessed August 1, 2006
28. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al.. The impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am J Heart 2004; 147:106-112
29. Williams B, hypertension therapy: Focus on surrogate markers such as endothelium, LVH atrial fibrillation, inflammation, albouminuria. JACC 2005; 45: 813-822
30. Halperin RO, et al. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006;47:45-50
31. Cohen JC, Boerwinkle E, Mosley T, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354: 1264-1272
32. Tall AR. Protease variants, LDL, and coronary heart disease. N Engl J Med. 2006;354:1310-1312
33. Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniadis C, Katsi V, Stefanadis C. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol 2006; 106:333-337
34. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006; 48:438-445
35. Balgent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278
36. Dahlof B, Sever PS, Poulter NR, et al, for the ASCOT Investigators. Prevention of CV events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo - Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering ARM (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005; 366:895-906
37. Sever PS and Poulter NP. Blood pressure reduction is not the only determinant of outcome. Circulation 2006; 113:2754-2763
38. Moser M. The ASCOT Trial. J Clin Hypertens (Greenwich) 2005; 7:748-750
39. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445
40. Atorvastatin Effective for Stroke Prevention: Presented at ESC; 2006. Available at: http://www.pslgroup.com/dg/25ADAE.htm. Accessed August 1, 2006
41. Goff DC, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006:113:647-656
42. Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913